439 related articles for article (PubMed ID: 29463563)
21. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
[TBL] [Abstract][Full Text] [Related]
22. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
23. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
[TBL] [Abstract][Full Text] [Related]
24. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Fantini M; David JM; Wong HC; Annunziata CM; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2019 Apr; 34(3):147-159. PubMed ID: 30601063
[TBL] [Abstract][Full Text] [Related]
25. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.
Alpdogan O; Eng JM; Muriglan SJ; Willis LM; Hubbard VM; Tjoe KH; Terwey TH; Kochman A; van den Brink MR
Blood; 2005 Jan; 105(2):865-73. PubMed ID: 15280205
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT.
Sauter CT; Bailey CP; Panis MM; Biswas CS; Budak-Alpdogan T; Durham A; Flomenberg N; Alpdogan O
Bone Marrow Transplant; 2013 Sep; 48(9):1237-42. PubMed ID: 23624821
[TBL] [Abstract][Full Text] [Related]
28. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
[TBL] [Abstract][Full Text] [Related]
29. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
30. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
31. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
[TBL] [Abstract][Full Text] [Related]
34. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
[TBL] [Abstract][Full Text] [Related]
35. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS; Kim HT; Costello C; Herrera AF; Locke FL; Maegawa RO; Savell A; Mazzeo M; Anderson A; Boardman AP; Weber A; Avigan D; Chen YB; Nikiforow S; Ho VT; Cutler C; Alyea EP; Bachireddy P; Wu CJ; Ritz J; Streicher H; Ball ED; Bashey A; Soiffer RJ; Armand P
Blood; 2020 Jun; 135(24):2182-2191. PubMed ID: 32478814
[TBL] [Abstract][Full Text] [Related]
36. Decrease post-transplant relapse using donor-derived expanded NK-cells.
Ciurea SO; Kongtim P; Soebbing D; Trikha P; Behbehani G; Rondon G; Olson A; Bashir Q; Gulbis AM; Indreshpal K; Rezvani K; Shpall EJ; Bassett R; Cao K; Martin AS; Devine S; Horowitz M; Pasquini M; Lee DA; Champlin RE
Leukemia; 2022 Jan; 36(1):155-164. PubMed ID: 34312462
[TBL] [Abstract][Full Text] [Related]
37. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
38. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
39. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
40. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
